Member Info for Winstanley

Planet V plays a crucial role in the newly announced advertising marketplace involving ITV, Sky, and Channel 4.

Planet V is owned and operated by ITV, which developed the platform as part of its strategy to enhance addressable advertising capabilities. The platform's collaborations utilise Planet V for its on-demand content. This partnership indicates a growing trend of cooperation among major broadcasters to leverage shared technology and data, ultimately benefiting advertisers by providing a more efficient and effective advertising solution.

Sky, Channel 4 and ITV announce joint launch of groundbreaking premium video advertising marketplace:

https://www.itv.com/presscentre/media-releases/sky-channel-4-and-itv-announce-joint-intent-launch-groundbreaking-premium-video

While pureLiFi specialises specifically in LiFi technology, GHH's involvement indicates a broader interest in optical communication technologies, plausibly including LiFi? Nonetheless, this article indicates the interest in these innovations:

https://thedefensepost.com/2025/06/16/uk-device-defense-connectivity/

GSK's Arexvy offers significant advantages over similar RSV vaccines, particularly in its long-term efficacy and safety profile. It is the only RSV vaccine with data demonstrating effectiveness over three seasons, showing a cumulative efficacy of 62.9% against RSV-related lower respiratory tract disease and 67.4% against severe cases in adults aged 60 and older. Arexvy utilizes GSK's proprietary AS01 adjuvant to enhance immune response, particularly in older populations, and has shown real-world effectiveness of approximately 77% in preventing emergency department visits and 83% in preventing hospitalizations during the 2023-2024 RSV season. Its favorable safety profile, with manageable side effects, and recent expanded recommendations for adults aged 50-59 at increased risk further solidify its position as a leading option in RSV prevention compared to competitors like Pfizer's Abrysvo and Moderna's mResvia. (Researched via AI).

'The tariff threats have "definitely been a catalyst" for pharmaceutical firms to plan more manufacturing in the US, a key source of sector profits, says Stephen Farrelly, global lead for pharma and healthcare at ING.

But, he adds, there are limits to what the threats can accomplish.

The pharma investments are set to unfold over time - a decade in some cases - in a sector that was poised for growth anyway.

https://www.bbc.co.uk/news/articles/clynl129kd2o

Everyone is preparing for potential challenges due to world events. With expected market fluctuations, investors are expected to seek safe havens. I predict that sectors like utilities, which provide essential services, consumer staples, pharmaceuticals, and healthcare - areas that maintain steady demand regardless of world circumstances - along with telecommunications, which offers vital communication services and infrastructure, will draw considerable attention. Needless to say, the defense/arms sector is likely to remain strong - and gold may break all records.

Hopefully, ITV won't get too dragged down and will regain its momentum.

Https://www.nbcwashington.com/news/local/rfk-jr-says-his-new-vaccine-panel-has-a-gw-university-professor-the-school-says-he-doesnt-work-there/3935974/

Is there an alternative? 'The argument has been bolstered by Ukraine’s ability to stall the advance of a larger adversary, aided by its use of relatively cheap underwater and airborne drones.'

https://uk.news.yahoo.com/aukus-cost-australia-368bn-better-200002946.html

The chances of belantamab mafodotin (Blenrep) being introduced in the U.S., Japan, or China appear promising. While the exact timeline for approval in the U.S., Japan, and China may vary, the combination of positive clinical data, existing approvals in other markets, and GSK's commitment to the drug's success suggests a favorable outlook for its introduction in these regions.

Https://pharmaphorum.com/news/nhs-starts-first-national-rollout-blenrep-myeloma

'Very smart drugs' being made available on the NHS.

The pharmaceutical company that stands to benefit from the news about belantamab mafodotin (Blenrep) is GlaxoSmithKline (GSK). As the developer and manufacturer of the drug, GSK is positioned to gain from its availability on the NHS in England, especially if it leads to increased sales and positive patient outcomes. The news may also enhance GSK's reputation in the oncology market and potentially attract further investment and interest in their other cancer therapies:

https://www.bbc.co.uk/news/articles/ckg4kj2nxjgo

Https://www.naval-technology.com/news/qinetiq-supports-uk-navy-readiness/?cf-view

Each to their own strategy, Jed.

The U.S. markets were positive for the sp when opening yesterday. We'll soon see if that trend continues or reverses today.

The first set of results after the 2026 football world cup will plausibly be awesome, IMO.

You'd be borderline foolish, IMO

£2+ this time next year.

ITV's very recent unveiling of three new commercial innovations, which are now active, at the ITV Showcase in Manchester is strategically timed. The next FIFA World Cup is scheduled to take in June 2026.

Overall, ITV's new commercial innovations are well-positioned to capitalise on the upcoming football World Cup. By providing advertisers with advanced tools to engage audiences and measure outcomes, ITV can enhance its advertising revenue while reinforcing its role as a key player in the media landscape. This strategic move not only benefits ITV but also supports brands in maximising their impact during one of the most-watched sporting events globally. The Dame is a genius!

https://www.itv.com/presscentre/presscentre/media-releases/itv-launches-new-commercial-innovations

ITV has unveiled three new commercial innovations:

https://www.itv.com/presscentre/presscentre/media-releases/itv-launches-new-commercial-innovations

GSK's prospects for Blenrep look promising as recent trial results show significant improvements in progression-free survival for multiple myeloma patients. With a potential U.S. return on the horizon, the drug's strong efficacy and manageable safety profile could position it well against competitors, potentially leading to substantial sales growth.

https://www.fiercepharma.com/pharma/eha-gsk-adds-fuel-adc-blenreps-comeback-case-new-pfs-data-ahead-potential-us-return

Looks like it's on a roll - £2+ this time next year!